All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering December 16, 2020
Details:
IPO funds will allow Virios to complete its Phase IIb, which will assess optimized doses of its antiviral for fibromyalgia, IMC-1, for Phase III, conduct chronic toxicology studies, manufacture more drugs, and prepare a Phase II proof-of-concept study in IBS.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ubidecarenone Coenzyme, Q-10
Therapeutic Area: Musculoskeletal Product Name: BPM31510
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: AdventHealth
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 15, 2020
Details:
The partnership is comprised of separate investigations that employ BERG’s Interrogative Biology® platform to examine potential biomarker signatures of age-related disease. This also includes Phase II trial of BPM31510 on platelet and skeletal muscle mitochondrial energetics.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Losmapimod
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
Details:
Fulcrum will present four posters on its integrated approach to the evaluation of FSHD patients, highlighting the progress made in the development of imaging and molecular biomarkers in FSHD and the design of clinical trials of losmapimod in FSHD patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NYX-2925
Therapeutic Area: Musculoskeletal Product Name: NYX-2925
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
Aptinyx has re-activated study sites and recommenced patient recruitment in a Phase 2 study of NYX-2925 in patients with fibromyalgia. Enrollment in the study had been suspended in March 2020 due to the escalation of the COVID-19 pandemic in the United States.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMC-1
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 25, 2020
Details:
The company's lead candidate, IMC-1, is a novel combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1activation and replication, with the end goal of reducing viral mediated disease burden.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMC-1
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 28, 2020
Details:
The company's lead candidate, IMC-1, is a novel combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1activation and replication, with the end goal of reducing viral mediated disease burden.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): UBX0101
Therapeutic Area: Musculoskeletal Product Name: UBX0101
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2020
Details:
There was no statistically significant difference between any arm of UBX0101 and placebo at the 12-week endpoint for change from baseline in WOMAC-A, an established measurement of pain in OA.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Losmapimod
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
Results from the interim analysis in the first 29 randomized subjects indicate that DUX4-driven gene expression did not show a separation from placebo at 16 weeks.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pegadricase
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status:
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
